Topical Tretinoin in Pregnancy and Breastfeeding
Avoid topical tretinoin during pregnancy, particularly in the first trimester, though the actual risk of major congenital malformations appears to be very low based on current evidence.
Pregnancy Use
Evidence Summary
The FDA classifies topical tretinoin as Pregnancy Category C 1. While oral retinoids are highly teratogenic and absolutely contraindicated in pregnancy 2, the data for topical tretinoin shows a different safety profile:
The most recent and highest quality evidence strongly suggests topical tretinoin does not increase malformation risk:
- A 2025 Nordic cohort study of 3.87 million pregnancies found no increased risk of major congenital malformations (MCM) with first-trimester topical retinoid exposure: adjusted RR 1.1 (95% CI 0.87-1.38) 3
- Among 2,172 exposed infants, 3.3% had MCM compared to 3.0% in unexposed infants 3
- A 2026 systematic review and meta-analysis of 3.6 million pregnancies confirmed no significant association with MCM (RR 0.83,95% CI 0.64-1.07) or spontaneous abortion (RR 0.99,95% CI 0.68-1.43) 4
Earlier studies support these findings:
- A 2015 meta-analysis of 654 exposed pregnancies found no significant increases in MCM (OR 1.22,95% CI 0.65-2.29), spontaneous abortion, stillbirth, or prematurity 5
- A 1993 study of 215 exposed women showed MCM prevalence of 1.9% versus 2.6% in controls (RR 0.7,95% CI 0.2-2.3) 6
Clinical Recommendation
Despite reassuring human data, the precautionary principle applies:
- Discontinue topical tretinoin if pregnancy is confirmed or planned 7
- The FDA label states: "There are no adequate and well-controlled studies in pregnant women. Tretinoin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus" 7
- For inadvertent first-trimester exposure: Counsel patients that available evidence does not demonstrate increased risk, but cannot completely exclude small increases in risk 4, 3, 5
Important Caveats
- Animal studies show teratogenicity at doses 8+ times human exposure, but topical absorption is minimal 7
- Thirty spontaneous reports of congenital malformations (including five cases of holoprosencephaly) have been reported over two decades of use, but no causal relationship established 7
- The Nordic study noted that limiting analysis to live births may underestimate both exposure prevalence and MCM risk 3
Breastfeeding Use
The safety of topical tretinoin during breastfeeding is unknown but likely low risk given minimal systemic absorption.
- It is not known whether tretinoin is excreted in human milk after topical application 1, 7
- The FDA label recommends: "Because many drugs are excreted in human milk, caution should be exercised when tretinoin is administered to a nursing woman" 7
- Practical approach: If used during breastfeeding, avoid application to the chest area to prevent direct infant contact 1
Risk-Benefit Consideration
Given the minimal systemic absorption of topical tretinoin and lack of evidence for harm, many experts consider it acceptable during breastfeeding with precautions, though formal guidelines do not explicitly endorse this practice. The decision should weigh the severity of the dermatologic condition against theoretical risks.
Alternative Options
For acne treatment during pregnancy:
- Topical azelaic acid (Pregnancy Category B) - safe alternative with comedolytic and anti-inflammatory properties 1
- Topical clindamycin (Pregnancy Category B) - safe for inflammatory acne 1
- Benzoyl peroxide (Pregnancy Category C) - generally considered acceptable 1
For acne treatment during breastfeeding:
- Same topical alternatives as pregnancy
- Systemic options like oral erythromycin may be considered if needed 1